Immix Biopharma, Inc. Common Stock (IMMX) Stock
Key stats
- Market cap
- $717.94M
- Price / Earnings ratio
- -15.0x
- EPS (TTM)
- -$0.88
- Volume
- Loading
- 52-week high
- $15.10
- 52-week low
- $3.16
Source: third-party data provider, as of November 13, 2026
Compare with IMMX
Recent news

Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study
Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study
IMMX

BofA Raises Odds Of Success For Immix Biopharma’s NXC-201 Therapy — Sees Over 190% Upside In IMMX Stock
BofA Raises Odds Of Success For Immix Biopharma’s NXC-201 Therapy — Sees Over 190% Upside In IMMX Stock
IMMX

IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law
IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law
IMMX

All You Need to Know About Immix Biopharma (IMMX) Rating Upgrade to Buy
All You Need to Know About Immix Biopharma (IMMX) Rating Upgrade to Buy
IMMX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 49.96
- MACD 12/26/9
- -0.44
- EMA 9 of MACD
- -0.65
- MACD histogram
- 0.21
- SMA 50
- $10.05
- Price below SMA 50
- EMA 50
- $9.37
- Price below EMA 50
- SMA 200
- $9.60
- Price below SMA 200
- EMA 200
- $8.92
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study
Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study
IMMX

BofA Raises Odds Of Success For Immix Biopharma’s NXC-201 Therapy — Sees Over 190% Upside In IMMX Stock
BofA Raises Odds Of Success For Immix Biopharma’s NXC-201 Therapy — Sees Over 190% Upside In IMMX Stock
IMMX

IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law
IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law
IMMX

All You Need to Know About Immix Biopharma (IMMX) Rating Upgrade to Buy
All You Need to Know About Immix Biopharma (IMMX) Rating Upgrade to Buy
IMMX

Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet
Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet
IMMX

Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?
Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?
IMMX

The 3 Best Speculative Stocks to Buy Now: September 2023
The 3 Best Speculative Stocks to Buy Now: September 2023
IMMX

3 Penny Stocks With the Potential to 10X in 2023
3 Penny Stocks With the Potential to 10X in 2023
IMMX

5 Short-Squeeze Candidates to Watch Today: IMMX, ALTM, GLTB, CRTX and TSRI
5 Short-Squeeze Candidates to Watch Today: IMMX, ALTM, GLTB, CRTX and TSRI
IMMX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Immix Biopharma, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Ilya Rachman M.B.A., M.D., Ph.D. | Co-Founder, CEO, Chief Scientific Officer & Chairman | 1973 |
| Mr. Gabriel Morris B.A. | President, CFO & Director | 1987 |
| Dr. Vladimir P. Torchilin D.Sc., MSE, Ph.D. | Scientific Co-Founder | 1947 |
| Dr. Graham Ross FFPM, M.D. | Chief Medical Officer & Head of Clinical Development | 1960 |
| Dr. David Marks MBBS, Ph.D. | Chief Medical Officer of Cell Therapy | — |
| Mr. Mel Davis-Pickett | Head of CMC Technical Development | — |
| Mr. Michael A. Grabow | Chief Commercial Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 49.96
- MACD 12/26/9
- -0.44
- EMA 9 of MACD
- -0.65
- MACD histogram
- 0.21
- SMA 50
- $10.05
- Price below SMA 50
- EMA 50
- $9.37
- Price below EMA 50
- SMA 200
- $9.60
- Price below SMA 200
- EMA 200
- $8.92
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $26.00
- Average
- $28.00
- High
- $30.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -3.0 | |||||||||||
| 2022 | -29.8 | -35.4 | -13.0 | -44.4 | +62.1 | +40.5 | -6.2 | -24.5 | -26.5 | -28.1 | +15.2 | +97.4 |
| 2023 | +17.1 | -20.9 | -12.1 | +31.4 | -29.4 | +35.2 | -30.9 | -1.0 | +49.3 | -16.4 | +53.9 | +33.3 |
| 2024 | -37.0 | -13.9 | -12.3 | -25.7 | -2.8 | +1.5 | -2.4 | +2.9 | -27.0 | +8.1 | +32.7 | +9.5 |
| 2025 | -11.8 | -8.7 | +3.7 | +31.1 | +14.7 | -20.4 | +24.2 | -16.2 | -8.3 | +82.7 | +16.8 | +29.8 |
| 2026 | +7.4 | +30.0 | +9.0 | +3.6 | -3.2 | +11.8 | -15.4 | +66.6 | -25.7 | -24.9 | +19.3 |



